Drug intelligence / Profile preview

fluticasone propionate + montelukast

Development stage
Phase 4
Lead developer
Merck
Modality
Small Molecules
Administration
Oral, Inhalation, Intranasal
01

Overview

Fluticasone propionate + montelukast is a fixed-dose combination of two pharmaceutical agents used primarily in the management of asthma and allergic rhinitis. Fluticasone propionate is a synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory agent by binding to the glucocorticoid receptor, thereby reducing airway inflammation and hyperresponsiveness. Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene type-1 receptors (CysLT1) on airway smooth muscle cells and other pro-inflammatory cells, inhibiting bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment triggered by leukotrienes. The combination has been shown to improve clinical efficacy in asthma control compared to monotherapy with either agent alone[1][7]. It is used for prophylaxis and chronic treatment of asthma as well as for relief of symptoms associated with allergic rhinitis[5][6]. Both drugs are available individually under various brand names but may be co-prescribed or formulated together in some markets.

Brand names
Flovent Diskus
Other names
fluticasone propionate and montelukastfluticasone + montelukastmontelukast sodium combined with fluticasone
02

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on fluticasone propionate + montelukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluticasone propionate + montelukast.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call